Workflow
Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis

Company Overview - Enlivex Therapeutics Ltd. is a clinical-stage company focused on macrophage reprogramming immunotherapy, developing Allocetra™, a universal cell therapy aimed at reprogramming macrophages to their homeostatic state [4]. Patent and Intellectual Property - The China National Intellectual Property Administration (CNIPA) has issued a notice of allowance for Enlivex's patent application number 2020800620493, which will provide intellectual property protection in China until at least 2040 for methods using Allocetra™ to treat osteoarthritis [1]. - The company anticipates that the patent will be officially issued in the first half of 2025 [1]. Clinical Trial Results - Enlivex reported positive interim data from a Phase I/II trial of Allocetra™ in patients with moderate to severe knee osteoarthritis, showing a statistically significant average pain reduction of 47.0% (P=0.0001) compared to baseline [6]. - The trial also indicated a 46% improvement in joint function and a 40% improvement in joint stiffness, with 83% of patients still considered responders after six months [6]. Osteoarthritis Context - Osteoarthritis is the most common form of arthritis, affecting over 32.5 million Americans and more than 300 million people globally, with projections indicating that 78 million Americans will have the condition by 2040 [3]. - The disease leads to significant healthcare burdens, including over one million hospitalizations annually in the U.S. for total joint replacement, highlighting the critical need for effective treatments [3].